Interestingly, NSCLC patients harboring KIF5B-RET fusions showed minimal response after RET TKI (RXDX-105) treatment, whereas the response rate was 67% in non-KIF5B-RET+ NSCLC patients [16]. This evidence concerns the gene KIF5B and non-small cell lung carcinoma.